The content on this site is intended for healthcare professionals only

ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Bookmark and Share

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 17 Jun 2009
Views: 13185
Rating:
Save
Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US
ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer

Related Videos

Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
ERMES study suggests a strategy of de-escalation with only cetuximab in first li...
Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )
14 Sep 2022
An overview of treatment advances in gastric cancer
Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA
An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )
18 Aug 2022
Optimum treatment strategy algorithm for mCRC
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Optimum treatment strategy algorithm for mCRC ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
15 Aug 2022
MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC
Dr Jonathan Strickler - Duke Cancer Institute, Durham, USA
MOUNTAINEER: Tucatinib in combination with trastuzumab for HER2-positive mCRC ( Dr Jonathan Strickler - Duke Cancer Institute, Durham, USA )
8 Aug 2022
Impact of BRAF-V600E mutation on the tumour microenvironment and associated geno...
Dr Mohamed Salem - Levine Cancer Institute, Charlotte, USA
Impact of BRAF-V600E mutation on the tumour microenvironment and associated genomic alterations in colorectal cancer ( Dr Mohamed Salem - Levine Cancer Institute, Charlotte, USA )
20 Jul 2022
New developments in the treatment of colorectal malignancies
Dr Richard Kim - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
New developments in the treatment of colorectal malignancies ( Dr Richard Kim - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
8 Jul 2022
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and...
Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )
30 Jun 2022
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advan...
Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )
17 Jun 2022

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation